A longitudinal study on respiratory viral infection for healthy volunteers

Sixteen singleplex real-time PCRs were employed for the detection of the following respiratory viral pathogens: parainfluenza viruses (PIVs) 1, 2, 3, and 4, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), enterovirus (EV)/rhinovirus (RV), human bocavirus (hBoV), human parechovirus (...

Full description

Saved in:
Bibliographic Details
Published in:Health science reports 2021-12, Vol.4 (4), p.e413-n/a
Main Authors: Morikawa, Saeko, Otsuka, Maki, Yumisashi, Takahiro, Motomura, Kazushi
Format: Article
Language:English
Subjects:
Asymptomatic
Families & family life
Genotype & phenotype
Health care
Infections
Influenza
Longitudinal studies
Questionnaires
Research Letter
Research Letters
Respiratory syncytial virus
Viral infections
Viruses
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sixteen singleplex real-time PCRs were employed for the detection of the following respiratory viral pathogens: parainfluenza viruses (PIVs) 1, 2, 3, and 4, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), enterovirus (EV)/rhinovirus (RV), human bocavirus (hBoV), human parechovirus (hPeV), adenovirus (AdV), human coronaviruses (hCoV) OC43, NL63, 229E, and HKU-1, and influenza virus (FluV) type C, and one-step real-time reverse transcription (RT)-PCR was used for detection FluV A and B. 3–5 METHODS Subjects Before beginning the study, we explained the study plan and methods to the healthy volunteers of one office and obtained written informed consent from them. TABLE 1 Prevalence of respiratory viruses in gargle specimens of participants ID Age (years) Sex Total no. of samples Condition (n) Prevalence% (positive samples) Sampling dates (M/D), viral species, and Ct value (viral load Log10 copies/uL) 01 41 F 19 Asymptomatic (5) 20.0 (1) 3/26 Ad Ct: 42.25 (0.92) Symptomatic (14) 14.3 (2) 1/4 HKU-1 Ct:37.99 (6.16) 1/9 HKU-1 Ct:40.05 (4.87) 02 29 F 21 Asymptomatic (0) 0.0 (0) Symptomatic (21) 14.3 (3) 11/8 RVA24 Ct:34.86 (7.18) 11/27 RVA24 Ct:32.84 (8.55) 12/4 RVA24 Ct: 34.96 (7.11) 03 43 F 21 Asymptomatic (9) 0.0 (0) Symptomatic (12) 8.3 (1) 1/4 PIV2 Ct:36.99 (6.92) 04 40 F 21 Asymptomatic (12) 8.3 (1) 2/19 229E Ct:24.47 (14.70) Symptomatic (9) 22.2 (2) 12/25 HKU-1 Ct:35.95 (7.43) 1/22 FluA Ct:40.92 (2.50) 05 47 F 20 asymptomatic (14) 0.0 (0) symptomatic (6) 7.4 (2) 2/13 EV/RV Ct:38.03 (5.03) 3/5 FluB Ct:35.88 (6.19) 06 54 F 20 Asymptomatic (15) 6.7 (1) 3/12 PeV Ct:39.96 (6.12) and Ad Ct:39.96 (2.48) Symptomatic (5) 20.0 (1) 2/19 FluB Ct:26.70 (13.04) 07 41 M 21 Asymptomatic (16) 0.0 (0) Symptomatic (5) 40.0 (2) 12/4 RVA103 Ct:26.08 (13.13) 12/11 RVA103 CT:42.94 (1.70) 08 30 M 21 Asymptomatic (16) 37.5 (6) 12/11 RVC8 Ct:29.90 (10.54) 12/18 RVC8 Ct:33.98 (7.77) 12/25 RVC8 Ct:33.37 (8.19) 1/9 RVC8 Ct:33.18 (8.32) 1/22 EV/RV Ct:36.99 (5.73) 3/26 RVC11 Ct:27.57 (12.12) Symptomatic (5) 60.0 (3) 11/27 RSV CT:37.95 (5.69) 12/4 RVC8 Ct:32.12 (9.04) 2/5 RVC8 Ct:32.98 (8.45) 09 49 M 21 Asymptomatic (14) 0.0 (0) Symptomatic (7) 42.9 (3) 3/5 EV/RV Ct:38.99 (4.34) 3/19 RVC44 Ct:37.13 (5.64) and Ad Ct:37.90 (3.88) 3/26 RVC44 Ct:25.75 (13.36) 10 47 F 21 Asymptomatic (6) 33.3 (2) 2/5 Ad Ct: 40.97 (1.79) 2/13 229E Ct:37.90 (5.61) Symptomatic (15) 13.3 (2) 12/4 RVC15 Ct:30.98 (9.81) 1/4 EV/RV Ct:37.97 (5.07) 11 41 F 20 Asymptomatic (12) 0.0 (0) Symptomatic (8) 25
ISSN:2398-8835
2398-8835
DOI:10.1002/hsr2.413